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Background: Growing evidence suggests that obesity is associated with systemic inflammation. 
The level of inflammation can be exacerbated by one or more existing food intolerances. 
Furthermore, studies have shown that diet quality, not quantity, plays an important role in 
potential inflammation caused by foods. It is therefore, important to determine if dietary patterns 
alone or in combination with increased adiposity have a greater effect on systemic inflammation 
and body composition. 
Objective: Hence, the purpose of this study is was to examine the effect of food elimination 
using the ALCAT food elimination protocol, on body composition and overall body 
inflammatory markers. 
Methods: One hundred thirty-one participants were randomly assigned to either a treatment 
(n=72) or a control (n=59) group in this pre- and post-test double blind experimental study. All 
participants followed a 4-week elimination diet based on ALCAT testing protocol, completed a 
medical symptoms questionnaire at the beginning and end of the study, had their blood drawn for 
inflammatory markers and provided anthropometric measurements for body composition 
analysis.. In additions Participants kept an exercise log and food log during the study. Within and 
between group differences in body composition and inflammatory markers were analyzed using 
repeated measures ANOVA. Significant main and interaction effects were analyzed using the 
Bonferonni post-hoc method for multiple comparisons. Univariate analysis of variance was 
utilized to examine body composition.  
Results: Both the treatment group and the control groups experienced significant decreases in 
CRP, MPO, and TNF-α; yet there were no statistically significant differences between the 
treatment and the control groups.  However, the treatment group was found to have a significant 
(p<0.05) decrease in SAA compared with the control group which showed no change in SAA. 
Analysis of body composition revealed a significant (p<0.05) decrease in lean body mass, body 
fat percentage, and waist circumference in both groups; however, the difference was not 
statistically different between the treatment and the control group even after adjustments for age, 
gender and baseline outcomes. 
Conclusions: Overall, there was little evidence to support the ability of elimination diets in 
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Over the last 20 years, there has been a dramatic rise in body weight. Currently, more 
than one third of adults in the United States are obese (1). Obesity is a major health concern, 
since it is strongly linked to coronary heart disease, insulin resistance, type 2 diabetes and non-
alcoholic fatty liver disease (1,2). Although the rise in obesity has many causes, inflammation is 
the most common feature which has been implicated in the pathophysiology of all the obesity 
related disorders.   
Inflammation is a protective response by the immune system to harmful stimuli, such as 
infection, acute illness, trauma, toxins, many chronic diseases and physical stress (2). Chronic 
inflammation is characterized by the prolonged presence of macrophages in the injured tissue, 
simultaneously destroying and healing the tissue during the inflammatory process (3-5). Chronic 
inflammation can lead to systemic inflammation which can impair digestion and absorption 
which can result in a decreased lean body mass and a decline in nutritional status (2,5). The role 
of inflammation in the pathology of rheumatoid arthritis (RA), inflammatory bowel diseases 
(IBD), and asthma are well recognized (5). Yet when obesity is present, the role of inflammation 





Numerous studies have shown that as visceral adipose tissue increases with weight gain 
so do pro-inflammatory cytokines such as C-reactive protein (CRP),interleukin 1-beta (IL-1-β), 
interleukin-6 (IL-6),myeloperoxidase (MPO), and tumor necrosis factor-alpha (TNF-α). The 
cascade of pro-inflammatory cytokines favors insulin resistance which may lead to more weight 
gain as fat.  It becomes a vicious cycle of increased inflammation and more deposition as fat (6-
8). Furthermore, the multitude of cytokines released in relation to obesity can change from 
advantageously protecting the body to damaging by leading to inflammatory diseases (2,4,5). 
The nutritional state of an individual can also affect inflammation. For example, undernutrition, 
which may occur with impaired digestion or absorption, dysfunctional metabolic processing or 
inadequate intake, can result in malnutrition and protein depletion (2). On the other hand, 
overnutrition promotes obesity-related health issues, such as diabetes, heart disease, 
hypertension, metabolic syndrome, and some cancers (2).  
Along with nutritional status, dietary intake may play a key role in the inflammatory 
process. Simple diet and lifestyle changes can positively affect obesity-related inflammation 
(2,9). Likewise, the level of inflammation can be exacerbated by one or more existing food 
intolerances. If food intolerance is present, it stimulates the fight or flight response and increases 
your cravings for that food. This in turn, promotes the greater consumption of that food which 
will lead to more inflammation. Continued exposure to intolerances provides constant pro-
inflammatory stimuli that increase the body’s inflammatory response resulting in tissue damage 
and loss of barrier function thus leading to systemic inflammation (5,10). What is unknown at 
this time is if one eliminates food intolerances from the diet will their systemic inflammation, as 
measured through CRP, IL-1β, IL-6, MPO and TNF-α, decrease, thereby, reducing insulin 




Antigen Leukocyte Cellular Antibody Test (ALCAT) is useful is identifying problematic 
foods in cell-mediated or delayed reactions (2). ALCAT diets require the elimination of 
intolerant foods and thus should decrease appetite, reduce systemic inflammation, enable weight-
loss and improve body composition (11). 
Body composition measurements are important in assessing fat mass (FM) and lean body 
mass (LBM) (12). FM includes essential and non-essential fats. LBM includes protein, water, 
carbohydrate, and minerals (12). Waist circumference (WC) measurement indicate regional body 
fat distribution and has been shown to correlate with visceral adipose tissue (12). 
 
Statement of the Problem 
The purpose of this study was to examine the effect food elimination will have on body 
composition and on body inflammatory markers using ALCAT testing.  
 
Independent Variables 
A food elimination diet based on ALCAT test results (treatment group) or a sham list of 
foods (placebo group) will be provided and followed for four weeks.   
 
Dependent Variables 
Body composition will be measured in relation to food elimination using FFM, LBM, 
body fat percent, abdominal WC, and fat mass for both pre- and post-4 week study.  
Body inflammatory markers such as CRP, IL-1-β, IL-6, MPO, SAA, and TNF-α will be 






The following hypotheses were investigated during the 4-week elimination program: 
1. Subjects randomly assigned to the ALCAT treatment group will have lower CRP at the 
end of the 4 week study compared to those receiving the placebo.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person 
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Body inflammatory markers 
Attribute: Comparison of pre- and post-study blood levels of CRP 
2. Subjects randomly assigned to the ALCAT treatment group will have lower IL-1-β at the 
end of the 4 week study compared to those receiving the placebo.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person 
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Body inflammatory markers 
Attribute: Comparison of pre- and post-study blood levels of IL-1-β 
3. Subjects randomly assigned to the ALCAT treatment group will have lower IL-6 at the 
end of the 4 week study compared to those receiving the placebo.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 




Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Body inflammatory markers 
Attribute: Comparison of pre- and post-study blood levels of IL-6  
4. Subjects randomly assigned to the ALCAT treatment group will have lower MPO at the 
end of the 4 week study compared to those receiving the placebo.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person 
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Body inflammatory markers 
Attribute: Comparison of pre- and post-study blood levels of MPO  
5. Subjects randomly assigned to the ALCAT treatment group will have lower SAA at the 
end of the 4 week study compared to those receiving the placebo.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person 
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Body inflammatory markers 
Attribute: Comparison of pre- and post-study blood levels of SAA  
6. Subjects randomly assigned to the ALCAT treatment group will have lower TNF-α at the 
end of the 4 week study compared to those receiving the placebo.  




Attributes: Elimination of foods decided by ALCAT based on individual blood 
tests; varies per person 
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Body inflammatory markers 
Attribute: Comparison of pre- and post-study blood levels of TNF-α 
7. Subjects randomly assigned to the ALCAT treatment group will have lower FM and 
higher LBM at the end of the study compared to the placebo group.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person  
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: FM and LBM 
Attributes: FM and LBM assessed using bioelectrical impedance (Biospace) 
8. Subjects randomly assigned to the ALCAT treatment group will have lower fat percent at 
the end of the study compared to the placebo group.  
Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person  
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Fat percent 
Attributes: Fat percent assessed using bioelectrical impedance (Biospace) 
9. Subjects randomly assigned to the ALCAT treatment group will have a lower abdominal 




Independent Variable: Food Elimination Plan 
Attributes: Elimination of foods determined by ALCAT based on individual blood 
tests; varies per person  
Control: Participants will receive a placebo food elimination plan  
Dependent Variable: Abdominal WC 
Attributes: Abdominal WC measured with a cloth tape anteriorly halfway between 







REVIEW OF LITERATURE 
 
Introduction 
Obesity rates have more than doubled from 13% to 35.7% in the United States and 
worldwide over the last two decades (1, 13). It is predicted by World Health Organization 
(WHO) that 2.5 billion people worldwide will be overweight with a body mass index (BMI) 
greater than 25 and 700 million people will be obese with a BMI over 30 by the year 2015 (14). 
Obesity is a major health concern since obesity is strongly linked to inflammation and a number 
of inflammatory related disorders, such as coronary heart disease, insulin resistance, type 2 
diabetes and non-alcoholic fatty liver disease (15,16).   
Numerous studies have shown that as visceral adipose tissue increases, pro-inflammatory 
cytokines such as CRP, IL-1-β, IL-6, MPO, and TNF-α also increase. The cascade of pro-
inflammatory cytokines favors insulin resistance leading to more weight gain as fat.  It becomes 
a repetitive cycle of increased inflammation and more deposition as fat (6-8, 15, 16, 18). 
Furthermore, the multitude of cytokines released in relation to obesity can change from 
protecting the body to leading to inflammatory diseases (2,4).The presence of low-grade 




is a standard indicator of adipose tissue accumulation (6,16) which promotes low-grade chronic 
inflammation (15-16). Adipose tissue is an active secretory organ that sends out and responds to 
signals that control appetite, energy expenditure, bone metabolism, endocrine and reproductive 
systems, insulin sensitivity, as well as immunity and inflammation (6, 16). 
Inflammation is a protective response of the immune system to harmful stimuli, such as 
infection, acute illness, trauma, toxins, many chronic diseases and physical stress (2). Chronic or 
prolonged inflammation occurs when the body continues to produce inflammatory mediators 
past the acute response phase (2). Chronic inflammation is characterized by the increased 
presence of macrophages in the injured tissue, which leads to tissue damage and healing the 
tissue during the inflammatory process (3). Chronic inflammation can lead to systemic 
inflammation which can negatively affect many functions of the body, such as digestion and 
absorption. Inflammatory conditions trigger the immune system to release eicosanoids (n-6 
eicosanoids, leukotriene B4, prostaglandin E2) and cytokines (CRP, IL-1-β, IL-6, MPO, TNF-α), 
which mobilize nutrients needed in the inflammatory process (2,20). As a result, cytokines, 
especially IL-1-β, IL-6, TNF-α, impact whole body metabolism, body composition and 
nutritional status (2). 
The link between poor nutritional status and impaired immune function has been firmly 
established (2,20). However, research regarding diet quality, inflammatory markers, and its 
subsequent effect on immunity is minimal (21,22). A study was conducted to look at the 
association between healthy eating patterns and immunity and inflammation in overweight or 
obese menopausal women (21). Boynton et al, found limited evidence that healthy eating habits 




study showed that higher diet quality was associated with lower levels of serum CRP or SAA 
(21). Furthermore, diet quality has been linked to inflammatory markers, specifically CRP and 
SAA, where the association is largely affected by adiposity. Consumption of a healthier diet 
potentially leads to a decrease in adipose tissue, which may result in decreased levels of 
inflammatory markers (21,22). Further research supports the relationship between diet quality 
and inflammation. In a systematic literature review, foods associated with increased serum levels 
of CRP and IL-6 included red meats, processed meats, low-fiber foods or refined grains, and 
alcohol (22). Inversely, consumption of foods such as fruits, vegetables, and whole grains 
showed decreased serum levels of CRP and IL-6 in the study participants (22). Additionally, the 
Framingham Heart Study reported that as BMI, visceral adipose tissue, subcutaneous tissue, and 
WC increased serum levels of CRP and IL-6 also increased (17). 
Diet and exercise are known to reduce inflammation (9,19).  It is well known that 
consuming a diet rich in fruits and vegetables, low in refined starches, sugar, saturated and trans-
fatty acids reduces the level of inflammatory cytokines.  Additionally, a decrease in CRP, IL-6 
and TNF-α has been found with diet-induced weight loss (4,20).  A study investigated the 
relationship between inflammation and food digestion and discovered that impairments in 
intestinal structure, digestive and absorptive function, and barrier function are a result of 
inflammation originating in the intestine or distant locations (23). Currently, it is unknown what 
effect the removal of food intolerances from the diet will have on the body. It is suspected that 
systemic inflammation, as measured through CRP, IL-1β, IL-6, MPO and TNF-α, will decrease, 




The level of inflammation can be exacerbated by one or more existing food intolerances. 
If food intolerances are present, they will stimulates the fight or flight response and increases 
food cravings. This in turn, makes one eat a larger serving of that food which will lead to more 
inflammation. Continued exposure to allergens provides constant pro-inflammatory stimuli 
which increase the body’s inflammatory response resulting in tissue damage and loss of barrier 
function thus leading to systemic inflammation (4). Joint pain is a common result of systemic 
inflammation. TNF-α and IL-1β are believed to promote cartilage damage and CRP has been 
shown to be elevated in patients with osteoarthritis. Therefore, cartilage breakdown in 
osteoarthritis may be worsened by inflammation (20). Activated macrophages at the site of 
inflamed cartilage secrete TNF-α and IL-1, which lead to the loss of the integrity of the cartilage 
in the joints (4). 
 
Food Intolerances 
Food allergy by definition is an abnormal immunologic response to a food that occurs in 
a susceptible individual (24). Allergic reactions usually occur immediately and every time the 
food is consumed, even in small amounts. Food allergy reactions are facilitated by 
immunoglobulin E (IgE) antibody (24). Unlike food allergy, food intolerance refers to a variety 
of non-immunologic reactions, which are mediated by the innate branch of the immune system, 
occurring after consumption of a particular food (24). These abnormal physiologic responses 
may be unpredictable due to a gamut of reasons such as intrinsic properties of the food or to 




reproducible, may be delayed, and often depend on the quantity of the food consumed (24,25). 
Food intolerances to foods have been reported to cause low-grade inflammation throughout the 
body (14). For example, consumption of fried, fatty, junk foods and sweets have been associated 
with increased systemic inflammation and elevated CRP levels (26). 
Prevalence of Food Intolerances in the US 
The prevalence of food allergy appears to be on the rise in Westernized cultures (24). For 
example, peanut sensitization tripled and reported peanut allergy in children doubled over only a 
five-year period in both the United States and United Kingdom (24). Although evidence 
indicates an increasing prevalence, a discrepancy between patient- perceived and physician-
confirmed food allergy exists. The prevalence of food allergy, with an immediate immunological 
response, is highest in infants and toddlers. Cow’s milk allergy is experienced by 2.5% of 
infants, and up to 8% of children under 3 years of age have allergy to a limited number of foods, 
mainly cow’s milk, egg, soy, peanut, wheat, fish, shellfish, or tree nuts (24). The prevalence of 
food allergy decreases slightly with age, affecting almost 4% of the general population (24,25).  
In contrast, food intolerance is more common than food allergies but usually go 
undiagnosed due to delayed symptomology or improper format of testing. Research has shown 
that upwards of 70-80% of the US population reports having symptoms associated with food 
intolerances (25). Yet, these individuals are not able to be diagnosed with a food allergy due to 






Cause of Food Intolerances 
 Research has found that some primary reasons for food intolerances are an imbalance of 
fatty acids, chemicals in foods that the liver cannot break down, impaired gut function, and 
inherited enzyme deficiencies or metabolic disorder (10,24). It is important to note that inherited 
enzyme deficiencies or metabolic disorders that cause intolerance to food will not change 
secondary to genetics but if properly addressed, moderate quantities of the problematic food may 
be tolerated (10,24). However, the remaining aforementioned factors have been linked to 
unhealthy food consumption where the avoidance of such food results in weight normalization, 
attenuation of inflammation and reduction of other inflammation-based health issues (10). 
Specifically, fatty acid imbalances may result from the overabundance of corn and soy in the diet 
which contains high omega-6 fatty acids. These omega-6 fatty acids promote high arachidonic 
acid levels which in turn promote chronic, pro-inflammatory cytokine production (10). 
Additionally, natural or synthetic chemicals in a variety of foods in today’s diet are difficult for 
the liver to effectively detoxify and thus activate the immune system (10). For example, 
salicylates occur naturally in many fruits and vegetables, and can induce a pharmacologically 
mediated adverse reaction in susceptible individuals. Some examples of food-related factors 
responsible for non-immunologic reactions include improperly stored fish that became 
contaminated with histamine, or the presence of tyramine in aged cheese, alcoholic beverages, 
and cured meats (24). Furthermore, decreased gut function occurs when the gut membrane is 
compromised. When this natural barrier is damaged, the immune system is called into action as 




Intolerances to foods are mediated by the innate branch of the immune system and thus 
follow a different pathway than pathogens (10). Food intolerances symptoms are dose-related, 
chronic and delayed (10). Inflammation, toxic free radicals, and immune chemicals are produced 
as a result of food intolerances (10). These products may lead to high risk of metabolic, chronic 
and degenerative diseases (10).  
 
Symptoms of Food Intolerances 
Cellular reactions to food can cause inflammatory reactions which have been linked to a 
number of chronic health problems such as obesity, diabetes, migraines, and asthma in addition 
to skin, heart, joint, and digestive disorders (14,20,25). The extra-intestinal manifestations and 
other reactions to foods, such as bloating and swelling in the hands, feet, ankles, abdomen, chin 
and around the eyes, may not display immediate symptoms but can present many hours later. 
Inflammation associated with food sensitivities can lead to weight gain. Fluid retention caused 
by inflammation and the release of certain hormones and cytokines, such as IL-6 and TNF-α, are 
the major causes of the weight gain (14,25) 
Poor digestion, malabsorption of nutrients, and thus reduced nutritional status are also 
symptoms of food intolerances. Research shows that impaired gut function such as digestion, 
absorption, and barrier function, result from inflammation (12,23). Intestinal inflammation can 
impair both digestion and absorption within the inflamed area as well as surrounding intestinal 
areas which makes proper digestion and adequate nutrition challenging (12,23). For example, in 




activity is reduced, the transit time of food and nutrients is decreased so contents travel through 
the intestinal tract quicker, and the absorptive mucosa cells may be damaged (12). Celiac disease 
is a condition where eating gluten triggers an immune response in the small intestine, resulting in 
inflammation of the mucosa. As a result, the villi become atrophied and flattened, thus impairing 
digestion and absorption (12). Diarrhea, abdominal pain, malabsorption, and weight loss are 
symptoms of Celiac disease (12). Some extra-intestinal manifestations of Celiac disease include 
skin rashes, muscle and joint pain, as well as fertility issues in females (12). Additionally, 
individuals with food intolerances tend to have poor food intake when not feeling well which 
exacerbates poor digestion and malabsorption of nutrients (12).  
 
Inflammatory Markers 
There are a number of inflammatory cytokines in the human body. Each cytokine serves 
a particular purpose during the inflammation process. In a number of studies, the increased 
presence of inflammatory cytokines has also been associated with obesity, where these cytokines 
produced and released by the white adipose tissue (WAT) are responsible for the chronic 
inflammatory state of obesity (16,27). In healthy individuals, adipocytes produce pro-
inflammatory cytokines such as IL-6 and TNF-α (2,6,16,20, 28). IL-6 then stimulates the 
synthesis of CRP in the liver, all of which is increased with obesity (2,17,28i). Rexrode et al, 
found a significant and positive association between  IL-6 and CRP and all levels of BMI, and 
WC (29). Another study found that BMI and percent body fat were significant predictors of 




was shown (28). Ma et al, from Zhejiang University in Hangzhou, China, reported that several 
types of obesity were associated with chronic low-grade inflammation (3). Research shows that 
isolation of one cytokine in the pathophysiology is unlikely and that a compilation of cytokines 
predict disease (17). Therefore, in the present study multiple inflammatory markers were 
investigated: CRP, IL-1-β, IL-6, MPO, SAA, and TNF-α. 
 
C-Reactive Protein  
CRP is a protein that is synthesized in the liver (3,30) and in healthy individuals its level 
is less than 2mg/L in healthy individuals (15). Therefore, elevated levels of CRP can be used as a 
strong biomarker of low-grade inflammation (3,15,18,30). IL-6 has been found to be strongly 
correlated with the synthesis of CRP in response to an increase in visceral adipose tissue. 
(26,30). Research shows a positive correlation between circulating CRP levels and BMI 
(15,18,29-31). Moreover, elevated levels of CRP are associated with increased risk of 
atherosclerotic diseases, stroke, cardiovascular disease and diabetes (15,29). Studies have shown 
that elderly individuals commonly have elevated serum levels of TNF-α and CRP (20).  A study 
looking at the relationship between adiposity with CRP and IL-6 found that higher CRP and IL-6 
levels were observed as BMI levels increased (29). Another study by Khaodhiar et al., concurs 
with this study and reported almost identical findings (18). Interestingly, Khaodhiar et al., found 
the association between CRP and BMI to be greater for men as opposed to women due to a 
higher amount of visceral adipose tissue in males (18). In contrast, Rexrode et al., reported this 




resulted in decreased levels of CRP, thus potentially decreasing their risk of cardiovascular 
disease and diabetes (29). These findings were further supported by research showing that a 
healthy diet and weight loss were found to reduce CRP levels (30). Additionally, a longitudinal 
study conducted to examine the effect of BMI on CRP found that as BMI and body mass 
remained stable, so did CRP levels which coincides with previous research that BMI is positively 
associated with CRP. (31). Overall, a loss in weight and a decrease in BMI has been shown to 
decrease levels of CRP in both males and females.  
 
Interleukin-1-Beta  
IL-1-β is an adipokine that is synthesized in human white adipose tissue, along with 
TNF-α and IL-6, and exhibits pro-inflammatory properties (20,27). IL-1-β, TNF-α and IL-6 are 
often used as markers to assess inflammation (32). IL-1-β plays a role in the regulation of SAA 
during the inflammatory process (33). IL-1-β initiates the production of cyclooxygenase-2 
(COX-2), an enzyme that is abundant in activated macrophages and other cells that are seen at 
the site of inflammation. COX-2 has been shown to be abundant in various carcinomas and to 









IL-6 is a pro-inflammatory cytokine that participates in both trauma-related acute phase 
response and stress-related inflammatory response (6). A general systemic inflammation can 
occur when the stress is chronic (6). IL-6 is synthesized in human adipose tissue and plasma 
concentrations increase with obesity (3,7) where expression of IL-6 is higher in visceral than 
peripheral adipocytes (7,20). IL-6 obtains pro-inflammatory activity either by itself or by 
increasing levels of IL-1-β and TNF-α (3). Additionally, IL-6 stimulates the liver production of 
CRP (3). IL-6 is an adipokine that is synthesized in human white adipose tissue, along with IL-1-
β and TNF-α, and exhibits pro-inflammatory properties (20,27). Obesity is related to increased 
circulating levels of these cytokines (17,20,27,34). In normal weight women with high a high 
amount of adipose tissue, both IL-6 and TNF-α concentrations were associated with fat mass 
distribution (27). Higher IL-6 levels were observed with higher BMI levels; lower IL-6 levels 
were reported with a decrease of BMI (18,29). Elevated IL-6 levels are associated with 
subsequent heart attacks and diabetes (29). 
 
Myeloperoxidase  
MPO is a heme protein that constitutes the major component of neutrophils. (32). 
Therefore, MPO enzyme activity is used to measure neutrophil function (32). Plasma MPO is 
involved in the releases reactive oxygen species (ROS) and thus may impart damage to proteins, 
carbohydrates, lipids, and nucleic acids that serve as biological structures (32). This destruction 




state of oxidative stress, increased amounts of neutrophil surround the affected area and release 
MPO into the bloodstream. Therefore, plasma levels of MPO enzyme activity serves as a 
biomarker of inflammation, especially when sepsis is present (32). 
 
Serum Amyloid A 
SAA is an acute phase protein from the apolipoprotein family associated with high 
density lipoproteins (HDL) in the blood. SAA is produced in the liver and regulated by IL-1, IL-
6, and TNF-α in response to inflammatory stimuli, such as stress, injury, infection, or trauma 
(33). Due to the quick response of SAA, similar to CRP, it is a sensitive biomarker for the acute 
inflammatory state (21,33).  SAA, along with IL-6 and TNF-α, are known to be elevated in obese 
individuals as these inflammatory markers are expressed in adipose tissue (33). Research shows 
that elevated systemic SAA concentrations are associated with impaired glucose tolerance and 
type 2 diabetes mellitus, independent of established type 2 diabetes risk factors, BMI, waist-to-
hip ratio, and body fat mass index (33). Research suggests that elevated SAA levels are not the 
cause of diabetes but a result of the pre-diabetes process (33). Limited research found that 
healthy eating patterns may contribute to decreased circulating SAA levels such that 
consumption of a healthier diet potentially leads to a decrease in adipose tissue, which may result 






Tumor Necrosis Factor-alpha 
TNF-α is an adipokine that is synthesized in human white adipose tissue, along with IL-
1-β and  IL-6, and exhibits pro-inflammatory properties (6,27). TNF-α in adipose tissue acts 
locally but can promote insulin resistance peripherally (7,20,34). Studies have shown that elderly 
individuals commonly have elevated serum levels of TNF-α and CRP (20). TNF-α affects lipid 
metabolism and is correlated with high triglyceride levels and low HDL cholesterol levels (20). 
In a study by DeLany, TNF-α was reported to elicit a chronic inflammatory state thus 
contributing to the onset of cancer, heart disease, arthritis, and many other health problems (6). 
This may be due to the fact that TNF-α stimulate the synthesis of IL-6, which in turn stimulates 
the synthesis of CRP  and thus contributes to the maintenance of chronic low-grade systemic 
inflammation, especially with the presence of obesity (15). Another study found that as BMI 
increases up to a BMI of 40, TNF-α also increases; above 40 there were no further increases of 
TNF-α (18). 
 
Downside of Systemic Inflammation 
Inflammation can cause alterations in gastrointestinal functions that last long after the 
acute inflammation has been resolved (20). There are nutritional consequences of cytokine-
modulated actions as a result of chronic inflammation. The brain, endocrine system, liver, 
muscles, blood and gastrointestinal tract are target areas of cytokine-modulated behavior. The 
brain will experience a sickness syndrome that includes fatigue, apathy, cognitive dysfunction, 




system displays a euthyroid sickness, anorexia and an increase in the metabolic rate which 
results in muscle wasting due to decreased food intake (2). Increased synthesis of positive acute 
phase proteins, decreased synthesis of negative acute phase proteins, increased fatty acid 
synthesis, increased lipolysis and decreased lipoprotein lipase are all seen in the liver which 
results in increased edema and hypertriglyceridemia. Increased insulin resistance is observed in 
the muscles and results in hyperglycemia (2). In the blood, decreased red blood cells production 
occurs as well as a redistribution of albumin, pre-albumin and iron which results in anemia and 
increased edema (2). However, the increase in white blood cells, primarily leukocytes, results in 
activated inflammatory mediators which can interfere with lipolysis and thus inhibit weight loss 
(10). Lastly, in the gastrointestinal tract, the rate of protein breakdown increases, the gastric 
secretions decrease, gastrointestinal mobility slow down, and emptying time increases, this 
combination results in decreased protein reserves (2).  
 
Body Composition 
Body composition is utilized in tangent with other assessment tools to provide a precise 
depiction of an individual’s overall health (2).  Anthropometric methods used to assess body 
composition are based on the theory that the body is made up of two chemically distinct sections; 
fat and fat-free mass (35). Areas of focus in this study are fat mass, fat percent, lean body mass, 
and WC. BMI was found to be independently associated with IL-6 and CRP and unfit-
overweight participants had significantly higher IL-6 and CRP (19). Studies show that diet-





Fat-Free Mass  
FFM consists of muscle (skeletal and non-skeletal), soft lean tissues, and the skeleton and 
is a mixture of water, protein, and minerals with muscle acting as the major protein source (35). 
FFM is a measurement used to assess body fatness or overweightness and obesity. In fact, FFM 
is often preferred over BMI since it is a more accurate assessment tool of LBM (36). FFM is 
expressed in kilograms (kg) (36). 
 
Percent Body Fat  
Body fat (BF) is the primary way the body stores energy and is sensitive to severe 
malnutrition (35). Percent BF is measurement used to assess body fatness in regards to 
overweightness and obesity (36). Often times, percent BF is preferred over BMI since it is a 
more accurate assessment tool of adiposity (36). Percent BF is expresses as a percentage (%) 
(36).  
In a study by Wong et al., the levels of IL-6 and CRP were measured with weight loss 
and again with a decrease in percentage of body fat; the results were similar (17). The results 






Lean Body Mass  
LBM is a component of body composition, calculated by subtracting body fat weight 
from the total body weight. This is calculated to distinguish between body fat mass and LBM 
(36). LBM has typically been used for prescribing proper levels of medications and for assessing 
metabolic disorders. (36). Research shows that LBM is superior to total body weight as a clinical 
measure as body fat is less relevant for metabolism (36). LBM is expressed in kg (36). 
 
Waist Circumference 
 WC measurement is an established assessment of abdominal visceral adipose tissue 
(6,12). WC is found by measuring the distance around the smallest area below the rib cage and 
above the umbilicus with the use of a non-stretchable tape measure (2,12). In obese individuals, 
the waistline may be more difficult to locate, therefore, finding the point halfway between the 
inferior surface of the ribs and the top of the iliac crest may be the best location for WC 
measurement on obese individuals (6). Measurements over 35 inches for women and over 40 
inches for men are considered independent risk factors for disease (2,6). However, these 
parameters may not be as useful for individuals with a BMI of 35 or more (2).  
 
Bioelectrical Impedance Analysis  
 Bioelectrical Impedance Analysis (BIA) is a technique to analyze body composition and 




and lower impedance than fatty tissue due to its electrolyte content (2). BIA is a safe, non-
invasive, portable and rapid method to measure body composition, particularly LBM (2,12). BIA 
is a reliable method for large populations (12). For the best results, the individual should be well-
hydrated, abstain from alcohol, caffeine, or diuretics in the last 24 hours and abstain from 
exercise in the last 4 to 6 hours (2). However, fever, electrolyte imbalance, and extreme obesity 
may affect the reliability of the measurements (2).  
 
ALCAT 
History and Purpose 
The ALCAT test utilizes a food sensitivity blood test to identify potential cellular allergic 
reactions for over 350 foods, chemicals and herbs (2,11,25). ALCAT is useful is identifying food 
intolerances in cell-mediated or delayed inflammatory reactions. These inflammatory reactions 
are linked to chronic health problems like obesity and diabetes, as well as skin, heart, joint, and 
digestive disorders (25). It is strongly recommended that the ALCAT test be followed up with a 
subject-specific elimination diet and clinical observation (2). ALCAT diets require the 
elimination of intolerant foods and thus should decrease appetite, reduce systemic inflammation, 








The ALCAT test measures the effect of the food on the cells in the innate immune system 
to determine if a food intolerance is present (10). Specifically, ALCAT is an indirect 
measurement of the presence of prostaglandins, cytokines, and leukotrienes released from the 
degranulation of leukocytes in the presence of an allergen and measures the change of leukocyte 
via an automated computer analysis, called the ROBOCat II (2,14). The degree of food 
intolerance is determined by comparing the size and volume of the leukocytes post reaction to 
the baseline leukocyte sample given by the individual (14). Based on the level of leukocyte 
reactivity when tested, the foods will be labeled as acceptable foods or as a mild, moderate, or 
severe intolerance (25). According to Kaats, et al., the ALCAT test was found to be an effective 
test that offers individualization to the patient being tested (11). Furthermore, blind studies have 
revealed that ALCAT is the most accurate test to support a strong correlation between clinical 
symptoms and food (10).  
 
Justification for Food Elimination 
 The purpose of a food elimination diet is to remove the suspected food(s) from the diet 
for specific time period, usually 4-12 weeks, and followed by a reintroduction phase where the 
food is brought back into the diet. Food elimination diets are designed on an individual basis (2) 
and in the case of this study the elimination diets for the ALCAT group were based on the 




the avoidance of the problematic food(s) will result in improved gut integrity and healed gut 
barrier, increased liver detoxification, and better overall nutritional status (10).  
Successful weight loss and effective healthy eating patterns rely heavily on proper 
identification of factors related to food intolerance (10). In a double blind study by Akmal et al., 
an 83.4% correlation was determined between ALCAT test results and a statistically significant 
number of patients exhibiting food sensitivity related extra-intestinal symptoms, such as 
migraines, irritable bowel syndrome, eczema and other conditions that are often observed as co-
morbidities in obese patients (14). Kaats et al., found that the ALCAT testing and corresponding 
diet plan, used by the ALCAT group and compared to the control group showed positive results, 
such as an improved body composition and a decrease in self-reported disease symptoms (11). 
According to the Baylor University study, evidence supports the effectiveness of ALCAT testing 
in improving BMI and/or weight when the participants followed the recommended elimination 
diet based on ALCAT testing (14). For example, in the Baylor University study, it was shown 
that 98% of the participants, following the elimination diets based on ALCAT testing, lost 
weight, which was primarily from fat loss, and/or saw improvements in overall body 
composition (14). Additionally, these participants reported improvements in physical 
performance, sense of well-being, abdominal bloating and digestive issues (14).  
 
Conclusion 
Research has shown that obesity is a major cause of systemic inflammation (30). 




important role in potential inflammation caused by foods (11,14,30). Additionally, it is important 
to determine if dietary patterns alone or in combination with increased adiposity have the 
greatest effect on systemic inflammation and body composition. Food intolerance is more 
common than food allergies. Research has shown that upwards of 70-80% of the US population 
reports having food intolerance experiences (25). Yet, intolerances to foods usually go 
undiagnosed due to delayed symptomology or improper format of testing. Hence, the purpose of 
this study was to examine what effect food elimination had on body composition and on overall 










One hundred forty-six participants were selected to take part in this study. Participants 
were recruited by posting an advertisement in the local paper, by posting flyers on campus or in 
fitness centers within a 50 mile radius of Northern Illinois University (NIU) DeKalb campus 
(Appendix A), and via social media such as Facebook and LinkedIn. Those individuals meeting 
the Disease Symptom Inventory (DSI) criteria of having at least two or more of the symptoms 
listed and rating them as “somewhat severe effect” were selected for the study. Participants 
completed a disease symptom inventory (Appendix B), a medical survey questionnaire 
(Appendix C), and an ALCAT screening form (Appendix D). Participants kept a three-day food 
record including two weekdays and one weekend day (Appendix E), kept an exercise log for one 
week (Appendix F), and had 25 mL of blood taken to assess food intolerances at baseline and 
levels of CRP,  IL-1-β, IL-6, MPO, SAA, and TNF-α, at baseline. Participants had an additional 
3.5 mL of blood taken on the last day of the 4-week long study to retest levels of CRP, IL-1-β, 
IL-6, MPO, SAA, and TNF-α. Those individuals who were pregnant, had hemophilia, or were 
under the age of 18 or over the age of 65 were ineligible to participate in the study.   




were required to give written consent to participate (Appendix G) in accordance with the study 
procedures approved by Northern Illinois University Institutional Review Board  (Appendix H) 
and the Institutional Biosafety Committee (Appendix I), prior to enrollment in this study. All 
participants were debriefed at the end of the study (Appendix J). 
 
Experimental Design 
This was a randomly assigned pre- and post-test double blind experimental study. 
Participants were assigned to groups using a random number chart.  On day one and the last day 
of the four-week long study, subjects reported to the nutrition laboratory at NIU to have 
anthropometrics and blood samples taken. The blood samples determined ALCAT results for 
200 foods (only on day one), 50 functional foods and medicinal herbs, and 50 chemicals and 
molds and inflammatory marker levels (both pre and post study).  
All participants were assigned and counseled on an individualized elimination diet plan 
based on ALCAT testing (n=73) or sham list of foods (n=73). This diet plan was followed for 
four consecutive weeks. An exercise log was completed to control for extraneous body 
composition changes.  
 
Data Collection 
The participants completed a three-day food record (two weekdays and one weekend 
day), a weekly exercise log, complete the disease symptom inventory and medical symptom 
inventory, had their height, weight, body fat percentage, lean body mass and abdominal WC 






Participants reported to the nutrition laboratory at NIU.  All body measurements were 
taken with participants in light weight clothing and bare feet.  Height was measured using a wall-
mounted stadiometer (Ayrton S-100 Prior Lake, MN). Weight, FM, percent fat, and FFM were 
assessed using bioelectrical impedance (InBody 520, Biospace Inc. Los Angeles, CA). 
BMI, using the standard equation (kilogram per meter squared), was calculated by the 
InBody 520. 
 Abdominal WC was measured with a cloth tape anteriorly halfway between the lowest 
lateral portion of the ribcage and the iliac crest.   
 
Blood Samples 
In addition to anthropometric data collection, participants had their blood drawn in the 
Nutrition Laboratory (308A Wirtz Hall) by trained phlebotomists while wearing gloves and a lab 
coat. After the subjects arm site was prepared by cleaning with an alcohol swab, either a 22 
gauge needle or a 21 or 23 gauge butterfly was placed in an arm vein in order to obtain blood 
samples. After the blood was taken, the venipuncture site was covered with gauze and slight 
pressure was applied to the site. The site was then covered with a band-Aid. The needles and 
gauze products covered with blood were disposed of in clearly labeled sharp containers which 
were available in the Nutrition Laboratory in 308A Wirtz Hall.  .  
Four blue top vials (4.5 mL each) containing 3.8 % buffered sodium citrate and one gold 
top serum separator (SST) was obtained. The Blue top blood sample assessed food sensitivities 
using ALCAT and the gold top was used to assess inflammatory markers CRP, IL-6, IL-1 β, 




collection. Blue top vials were immediately inverted several times to ensure proper mixing. The 
gold top vial was centrifuged (Compact II Centrifuge made by Clay-Adams, Beckton Dickinson 
Company) at 3000 RPM for 15 minutes to separate the plasma cells from the serum. All vials 
were placed into the slots of the foam sleeves which were then be placed into a biohazard 
specimen bag.  The requisition form was placed in the front pouch of the specimen bag. The strip 
covering the blue adhesive was removed and the bio-hazard specimen bag was sealed. The 
specimen bag with vials and requisition were placed into a silver insulated bag and the bag was 
sealed. The insulated bag was placed in the box provided by ALCAT.  The specimen were 
placed into the pre-paid UPS Laboratory Pak and sealed tightly.  The specimens were transported 
to the local UPS store and sent overnight to Cell Science Systems 852 South Military Trail 
(ALCAT headquarters) in Deerfield Beach, FL.  
 
Diet Analysis 
Diet analysis was performed using a three-day food log that the participants in this study 
completed. Participants were instructed on how to approximate serving sizes and how to identify 
ingredients in their food so that the most accurate analysis can occur. It was explained that the 
more accurate the log, the more accurate the diet analysis will be. The purpose of this was to 
determine if the participants were following the recommended elimination diet plan. Diets were 
to be analyzed to the nearest total calorie and nearest ½ gram of protein. NutritionCalc Plus 
(McGraw-Hill Companies, Columbus, OH, 2009) was utilized for the data entry and analysis of 







 Descriptive measures were analyzed using a one-way analysis of variance 
(ANOVA).  Within and between group differences in body composition and inflammatory 
markers at day one and at the end of the four-week elimination diet were analyzed using repeated 
measures ANOVA. Significant main and interaction effects were analyzed using the Bonferonni 
post-hoc method for multiple comparisons. This data was expressed as m + SD.  Univariate 
analysis of variance was utilized to examine body composition. Three response variables (lean 
body mass, percentage BF, and WC) were analyzed with univariate regression adjusted by age, 
gender, and baseline outcomes. This data was expressed as F value and significance (p) level. 
Statistical significance for all data analysis was accepted at the p<0.05 level of confidence. Data 
was analyzed by using the Statistical Package for Social Sciences (SPSS) for Windows (Version 









The purpose of this study was to determine whether the elimination of foods determined 
to cause an inflammatory response would lead to a decrease of inflammation and an 
improvement of body composition.  In this double blind study, subjects were randomly assigned 
by Cell Science Systems to either the control group (n=59) in which the participants received a 
placebo elimination diet or the treatment group (n=72) in which the participants were given an 
accurate list of foods they had severe and moderate reactions to, based on ALCAT testing. Those 
foods were eliminated for 4 weeks.  
 
Participants 
One hundred forty-six participants were enrolled in the study and completed the initial 
data collection process. The participants were randomly assigned to the treatment or control 
group. Fifteen participants were withdrawn from the study due to lack of response to a 
scheduling email for the follow-up appointment. One hundred thirty-one participants, control 
group (n=72) and treatment group (n=59), completed all phases of the study.  
 There were no significant differences in age, BMI, percentage BF, height, WC, weight, 





treatment or control group at the start of the study. Descriptive data is shown in Table 1 and 
Figure 1. 
 
Table 1: Physical Characteristics of Subjects 
Variable Group Data 




Age (years) Control 
Treatment 
34.85 + 11.52 
34.79 + 12.91 
BMI Control 
Treatment 
27.15 + 6.56 
27.45 + 5.93 
Body Fat % Control 
Treatment 
31.35 + 10.71 
31.59 + 9.51 
Height (cm) Control 
Treatment 
168.33 + 8.28 
167.51 + 11.69 
Waist Circumference (in) Control 
Treatment 
88.22 + 13.20 
90.69 + 17.16 
Weight (kg) Control 
Treatment 
77.48 + 18.66 
78.76 + 20.58 
Medical Questionnaire Day 1 Control 
Treatment 
56.20 + 31.22 








Figure 1: Physical Characteristics of Subjects 
 
Inflammatory Markers 
CRP, MPO, SAA, TNF-α 
Four inflammatory markers, CRP, MPO, SAA and TNF-α, showed a significant decrease 
at the end of the four-week study. There was a significant decrease in CRP levels for both the 
treatment group (p=0.0024) as well as for the control group (p=0.0259) during the study. (2.44 + 
3.83to 1.09 + 1.35 and 2.54 + 4.43 to 1.18 + 1.24, respectively). Similarly, there was a 
significant decrease in MPO levels for both the treatment group (p<0.0001) as well as for the 
control group (p<0.0001) during the study (302.78 + 245.85 to 181.06 + 134.39 and 352.00 + 
288.25 to 167.81 + 112.00, respectively). Likewise, there was a significant decrease in TNF-α 
levels for both the treatment group (p<0.0001) as well as for the control group (p<0.0009) during 
the study. (0.81 + 0.50 to 0.67 + 0.32 and 0.74 + 0.14 to 0.65 + 0.14, respectively). However, 
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control group (p=0.0761) during the study. (51.08 + 46.96 to 30.92 + 37.91 and 42.60 + 40.68 to 
31.55 + 35.10, respectively). Full results can be found in Table 2 and Figures 2-4. 
 
IL-1-β and IL-6 
There were no significant decreases in IL-1-β or IL-6 levels for either the treatment or the 
control group during the 4 week study.  
 
Comparison of Changes in Inflammatory Markers 
 When analyzing the levels of inflammatory markers at day one and day thirty for control 
and treatment groups, mixed results were found. There was a significant decrease in CRP, MPO, 
TNF-a in both the control (p=0.0259, p<0.001, p=0.009, respectively) and treatment groups 
(p=0.0024, p<0.001, p<0.001, respectively). There was a significant decrease in SAA for the 
treatment group (p=0.0017) but not the control group. There was no significant decrease in IL-1-













Table 2: Inflammatory Marker Changes over the Course of the 4-Week Study 
Variable Group Day 1 Day 30 Comparison - Day1 & Day 30 
CRP Control  
Treatment 
2.54 + 4.43 
2.44 + 3.83 
1.18 + 1.24 
1.09 + 1.35 
1.36 + 4.57* 
1.35 + 3.63* 
IL-1-β Control 
Treatment  
0.46 + 0.36  
0.63+ 1.76 
0.40 + 0.47 
0.45 + 0.98 
0.06 + 0.60 
0.19 + 0.81 
IL-6 Control 
Treatment  
3.34 + 1.03 
3.62+ 2.59 
3.25 + 0.68 
3.60 + 1.51 
0.08 + 0.62 
0.02 + 1.87 
MPO Control 
Treatment  
352.00 + 288.25 
302.78 + 245.85 
167.81 + 112.00 





42.60 + 40.68 
51.08 + 46.96 
31.55 + 35.10 
30.92 + 37.91 
11.05 + 47.02 
20.15 + 52.37* 
TNF-α Control  
Treatment 
0.74 + 0.14 
0.81 + 0.50 
0.65 + 0.14 
0.67 + 0.32 
0.09 + 0.19* 






























































Univariate Analysis of Variance was utilized to examine body composition. Three 
response variables (lean body mass, body fat percentage, and WC) were analyzed with univariate 
regression adjusted by age, gender, and baseline outcomes.  
 
Lean Body Mass 
There was a significant increase in LBM from day one to day thirty (F=5.793, p=0.018). 
According to the estimated marginal means of LMB at day thirty, the treatment group had a 
higher LBM mean than the placebo group. However, when factoring in age and gender and when 
comparing the treatment and control groups in relation to LBM, no significant correlations were 
found.  Full results can be found in Table 3. See Figure 5. 
 
Body Fat Percentage 
Overall, a significant decrease in body fat percent was found (F=527.628, p<0.001).  
There was a significant decrease in body fat percent from day one to day thirty (F=2099.220, 
p<0.001). According to the estimated marginal means of body fat percent at day thirty, the 
treatment group had a higher body fat percentage mean than the placebo group. When factoring 
in age and gender and when comparing the treatment and control groups in relation to body fat 








Overall, a significant decrease in WC was found (F=145.605, p<0.001).  There was a 
significant decrease in overall WC from day one to day thirty (F=562.339, p<0.001). According 
to the estimated marginal means of WC at day thirty, the treatment group had a lower WC mean 
than the placebo group. However, when factoring in age and gender and when comparing the 
treatment and control groups in relation to body fat percentage, no significant correlations were 
found. See Figure 7. 
 
Table 3: Changes in Body Composition over the Course of the 4-Week Study 
Variable Comparison Factor F Value Significance Level 


















Body Fat % D30 Overall change 
Age 
Body Fat %  D1 
Group 
Gender 






































Figure 5: Estimated Marginal Means of Lean Body Mass at Day 30 
 
 





Figure 7: Estimated Marginal of Means of Waist Circumference at Day 30 
 
MQ Day 1 and MQ Day 30 
A Pearson’s correlation was run to determine the relationship between 131 participants’ 
MQ Day one and MQ day thirty scores. Pearson correlation for the data revealed a strong, 




Both treatment and control groups were provided an elimination diet to follow for four 
consecutive weeks. The treatment group was found to have 88.9% dietary compliance (n=64), 




non-compliance (n=9) existed for both groups combined. Full results can be found in Table 4. 
See Figure 8. 
 
Table 4: Dietary Factors over the Course of the 4-Week Elimination Diet 
Factor Group Total in Group Number Participants 











































Dietary Compliance (n=131) 
Control (58/122) 
Treatment (64/122) 





Both treatment and control groups were provided an elimination diet to follow for four 
consecutive weeks. The treatment group was found to have 66.7% of participants with gluten 
intolerance (n=48), whereas the placebo group was found to have 45.8% of participants with an 
intolerance to gluten (n=27). No gluten intolerance was found for 42.7% of both groups 
combined (n=56). See Figure 9.  
 
 
Figure 9: Gluten Intolerance Discovered During the 4-Week Study 
 
Fluoride Intolerance 
From the treatment and control groups, fifty-three participants were found to have 
fluoride intolerance. The treatment group was found to have 45.8% fluoride intolerance (n=33), 
whereas the placebo group was found to have 34.5% fluoride intolerance (n=20). No Fluoride 
intolerance was found for 59.2% of both groups combined (n=77).  See Figure 10. 
 
 
Gluten Intolerance (n=131) 
Control (27/75) 
Treatment (48/75) 









From the treatment and control groups, 47 participants were found to have glyphosate 
intolerance. The treatment group was found to have 54.2% glyphosate intolerance (n=39), 




Figure 11: Glyphosate Intolerance Discovered During the 4-Week Study  
Fluoride Intolerance (n=131) 
Control (21/54) 
Treatment (33/54) 
No Intolerance (77) 
Glyphosate Intolerance (n=131) 
Control (9/48) 
Treatment (39/48) 








This was the first study to test whether food elimination based on ALCAT testing would 
alter body composition and decrease body inflammation. Unfortunately, none of the nine 
hypotheses tested were supported as evidenced by the results. The findings of this study suggest 
both groups had significant decreases for three of the six inflammatory markers, CRP, MPO, 
TNF-α. In addition, SAA was found to significantly decrease in the treatment group only. 
However, when comparing the treatment and control groups for each inflammatory marker, there 
were no significant differences between them. Similarly, both treatment and control groups had 
significant decreases for LBM, percentage BF, and WC from day one to day thirty. The findings 
of this study concur with other studies in that a decrease in WC is strongly correlated with 
decreased levels of CRP (29,30). Previous studies also have found that diet quality was inversely 
associated with CRP and SAA levels such that as diet quality improved, levels of CRP and SAA 
decreased (21). The findings of this study differ from previous studies that found a significant 
treatment effect with reduction in IL-6 and TNF-α based on ALCAT testing and associated 
elimination diets (10).  Additional studies have shown elimination diets based on ALCAT testing 
to significantly improve body composition, specifically decreased body fat percent, and 






Both the treatment group and the control groups experienced significant decreases in 
CRP, MPO, and TNF-α; yet, the treatment group was not found to be statistically different than 
the control group.  Studies have shown that diet induced weight loss decreases CRP, IL-6, TNF-
α, which may provide some rationale for the observed decreases in CRP & TNF-α along with 
improved body composition (20,30). According to Rexrode, et al., CRP is more strongly 
correlated with WC than IL-6, which may explain a decrease in CRP and not IL-6 (29,30). 
Additionally, the treatment group was found to have a significant decreased in SAA, whereas the 
control group showed no significant change in SAA levels. SAA is inversely associated with diet 
quality and obesity, where a high quality diet and decrease in adipose tissue was associated with 
lower levels of SAA or CRP (21). No significant findings were associated with IL-β-1 and IL-6 
for either group.  
Overall, there was little evidence to support a treatment effect of elimination diets based 
on ALCAT testing on the decreased levels of overall body inflammation. This is most likely due 
to the inclusion of chemicals, molds, medicinal herbs, and functional foods, in addition to food 
for the elimination diets. It is suspected that lack of knowledge of foods containing these items 
decreased dietary compliance. Although not part of the initial focus of this study, an unexpected 
and interesting finding was that dietary compliance, and specific intolerances to gluten, fluoride 
and glyphosate, may have skewed the final results. Dietary compliance is importance to consider, 
especially when analyzing the aforementioned intolerances because the control group was more 
compliant (98.3%) than the treatment group (88.9%). In regards to gluten intolerance, about half 
of control group were found to have gluten intolerance. Therefore, if told to avoid similar items 




gluten all together will decrease inflammation. This potentially skewed the treatment effect. 
Conversely, about half of treatment group was fluoride and glyphosate intolerant. If the 
treatment participants were not avoiding tap water (drinking, cooking or adding to foods) or 
foods containing glyphosate, this could have also skewed results and decreased the treatment 
effect. The skewed results would also occur if the control group, which had a better compliance 
rate, was avoiding glyphosate.  
Furthermore, because the control group eliminated ingredients found in numerous other 
products, total body inflammation decreased; thus creating skewed result of the treatment effect. 
For example, sunflower oil is an ingredient found in many commercial food items. In order to 
effectively eliminate sunflower oil, fast foods and commercial snack foods also must be 
eliminated. Although the individual intolerant to the sunflower oil, eating a healthier, higher 
quality diet leads to a reduction of adiposity which can further lead to decreased levels of body 
inflammation (2,9,21). Had this not occurred, it is suspected that a significant treatment effect 
would have been evident.   
 
Body Composition 
Analysis of body composition revealed a significant decrease in lean body mass, body fat 
percentage, and WC from day one to day thirty; however, the treatment group was not found to 
be statistically different from the control group even after adjustment for age, gender and 
baseline outcomes. The findings of this study differ from previous studies that found a 
significant positive correlation between elimination diets based on ALCAT testing and improved 
body composition (11,14).  One reason may be in how the elimination diets for the treatment 




from the most severe and moderate categories and not the mild category.  Had the treatment 
elimination diets included the mild category, it is suspected that a significant treatment effect in 
regards to decreased inflammation and improved body composition would have been found. 
Additionally, the control group received a placebo list of foods to avoid but some lists included 
food items that closely resembled or were associated with foods on the participant’s accurate list. 
This created mixed results and thus no significant difference between the treatment and control 
groups.  
 
Medical Symptom Questionnaire 
Comparison of the day one with the day thirty medical symptom questionnaire revealed a 
strong, positive correlation between day one and day thirty. Collectively, medical symptomology 
improved over the course of the four-week study for a large percentage of the 131 participants. 
No analyses were run to determine which group showed the greatest improvement. Similar 
studies have examined the relationship of medical symptomology and food sensitivities with a 
Disease Symptom Inventory (DSI), however, this study utilized the self-reported Medical 
Symptom Questionnaire (MQ) to assess such a relationship (11). 
 
Dietary Factors 
In regards to dietary compliance, the control group was found to have a higher percentage 
of dietary compliance than the treatment group. This may partly be due to the complexity of the 
elimination diets as the diets included foods, functional foods, medicinal herbs, chemicals and 
molds. Nutritional education was provided to participants along with the elimination diets to 




was done in previous studies (11). Other intolerances to gluten, fluoride, and glyphosate were 
present in both groups. Despite offering nutrition education, lack of knowledge or understanding 
regarding foods containing gluten and how these chemicals affect certain foods or beverages 
may have decreased dietary compliance unknowingly on behalf of the participants.   
Approximately 65% of the participants that finished the study completed a 3-day food 
log. Due to the lack of return rate, the results were not analyzed as these numbers may not be 
entirely representative of the group as a whole. 
 
Conclusion 
Overall, there was little evidence to support a treatment effect of elimination diets based 
on ALCAT testing on the decrease of overall body inflammation and body composition. This is 
most likely due to how the elimination diets were administered, as the items to avoid were vague 
and overwhelming, along with poor dietary compliance of the treatment group. Furthermore, it is 
suspected that a significant treatment effect in regards to decreased inflammation and improved 
body composition would have been found, if the following conditions were met: 1) only 
food/beverage items were included in the elimination diets (exclude chemicals, molds, medicinal 
herbs, and functional foods, 2) the treatment elimination diets included the mild category and 3) 
the placebo lists of foods to avoid were clearly different from the accurate list of foods with no 









LIMITATIONS AND FUTURE RESEARCH 
 
Limitations 
The ALCAT testing consisted of 200 foods, 50 functional foods and medicinal herbs, and 
50 chemicals and molds. As a result, the elimination diets were complex; requiring a lot of 
education to make sure participants knew exactly foods/beverages were associated with the 
functional foods, medicinal herbs, chemicals and molds and thus what to avoid. Future studies 
might consider ALCAT testing for foods only to increase participant diet compliance and an 
improved treatment effect. It is also recommended that elimination diets specifically list food 
items to be avoided to increase diet compliance.   
Additionally, mixed treatment results were observed due to conflicting placebo 
elimination diets. Many of the placebo elimination diets given to participants in the control group 
included items closely related to, or contained in food/beverage items with which the participant 
was intolerant. For example, baker’s yeast was on multiple placebo lists where the participants 
had gluten as a reactant food on the true results; by eliminating food/beverage items with baker’s 
yeast, gluten was also eliminated. This resulted in the participants experiencing a slight treatment 





extreme caution when assigning placebo elimination diets so that foods to be avoided during the 
course of the study are not associated with true reactant food items.  
Conversely, the elimination diets provided to the treatment group were not inclusive 
enough. The treatment group received reactant items to avoid from the most severe (red) and the 
moderately severe (orange) intolerance lists, but not from the mildly severe (yellow) list. As a 
result, more items from the mildly severe list have the chance to be consumed more frequently, 
have the potential to become a moderate or severe intolerance and thus create more inflammation 
in the body while simultaneously preventing improved body composition. It was also noted that 
many participants had extensive mild intolerance lists, yet relatively minimal severe and 
moderate intolerance lists. Due to the continued consumption of the mildly intolerant items, 
inflammation in the body increased while simultaneously preventing improved body 
composition. Both of these circumstances allowed for mixed results of treatment effect. 
Participants were asked to maintain their exercise regimen throughout the study based on 
the self-reported activity level on the day one exercise log. The pre- and post-study exercise log 
was used to ensure this consistency, however, many participants reported changing the exercise 
regimen during the study.  Additionally, not all participants returned the day thirty exercise log. 
Studies using a more accurate protocol to monitor exercise regimen may yield different results. 
 
Future Research 
A future study could use the protocol for a four-week elimination diet but simplify the 
content of the elimination diet to food/beverage items only. A simpler, more specific list of foods 
to eliminate would better assist the participants with dietary compliance. A more inclusive 




would better encompass the factors suspected to increase inflammation and allow for a more 
accurate treatment effect when comparing the control and treatment groups. Future studies could 
use the same protocol for Three-Day Food Logs but employ a more stringent plan to increase the 
return rate. A future study could use a more accurate protocol to monitor exercise which may 
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ATTENTION:  Adults 18 to 75 years of age 
 
Do you crave sweets? 
Do you experience digestive issues after eating certain foods?  
Does your body ache and you cannot figure out why?  
 
If you have answered YES to any of these questions, you might be eligible to participate in a  
Nutrition Research Project in Spring 2014 
 
Who’s Requested? 
 Males and Females aged 18 years to 65 years of age 
 People with food intolerances, nasal stuffiness, chronic tiredness, GERD or eczema.  
 People with recurrent anxiety, recurrent depression, insomnia or stressed out 
 Exclusion criteria includes pregnant women and people with bleeding disorders 
 
What is Required of You? 
 Complete a Disease Symptom Inventory and Medical Symptom Questionnaire 
 Complete pre- and post- study blood work & body composition measurements 
 Follow an individualized elimination diet for 4 weeks 
 Complete 3-day food log and weekly exercise log 
 
Why? 
 To determine effect of food elimination on body inflammation and body composition 
 
What are the Benefits to you? 
 FREE ALCAT allergy test for 200 foods - $700 value 
 FREE individualized elimination diet based on ALCAT test results 
 FREE analysis of your diet 
 FREE report of body composition measurements using special scale 
 FREE lab work to test the level of inflammation in your body - $1,000 value 
 
Who to Contact?                                                          
 Dawn Herbig at elimdietstudy@yahoo.com 
 































THE DISEASE SYMPTOM INVENTORY (DSI) 
Please rate each of the following disease symptoms for the extent to which they are 
currently bothering you using the following rating scale: 
0 = I do NOT have this symptom 
2 = A Mild Effect 
4 = A Severe Effect 
1 = A Very Mild Effect 
3 = A Somewhat Severe Effect 
5 = An Extremely Severe Effect 
 
1. _____ Migraine Headaches 
2. _____ Irritable Bowel Syndrome 
3. _____ Inflammatory Arthritis 
4. _____ Gastro Esophageal Reflux 
5. _____ Recurrent Sinusitis with Infection 
6. _____ Tension Fatigue Syndrome 
7. _____ Eczema 
8. _____ Recurrent Anxiety 
9. _____ Recurrent Depression 
10. ____ Insomnia 
11. ____ Low Self-Esteem 
12. ____ Chronic Tiredness 
13. ____ Binge Eating 
14. ____ Chronic Tension  
15. ____ Lack of Energy 
16. ____ Food Allergies 
17. ____ Feeling Under Stress 
18. ____ Craving for Sweets 
19. ____ Cravings for Foods other than 
Sweets 
20. ____ Anorexia 
21. ____ Bulimia 
22. ____ Overeating 
23. ____ Other (write in: 
____________________________________) 

































Medical Symptom Questionnaire 
 
Name _____________________________ Date _________________   
 
Rate each of the following symptoms based upon your typical health profile for: 
    Past 30 days    Past 48 hours 
 
Point Scale 0 - Never or almost never have the symptom 
 1 - Occasionally have it, effect is not severe 
 2 - Occasionally have it, effect is severe 
 3 - Frequently have it, effect is not severe 
 4 - Frequently have it, effect is severe 
 
HEAD ________ Headaches 
 ________ Faintness 
 ________ Dizziness 
 ________ Insomnia Total ________ 
 
EYES ________ Watery or itchy eyes 
 ________ Swollen, reddened or sticky eyelids 
 ________ Bags or dark circles under eyes 
 ________ Blurred or tunnel vision 
  (does not include near or far-sightedness) Total ________ 
 
EARS ________ Itchy ears 
 ________ Earaches, ear infections 
 ________ Drainage from ear 
 ________ Ringing in ears, hearing loss  Total ________ 
 
NOSE ________ Stuffy nose 
 ________ Sinus problems 
 ________ Hay fever 
 ________ Sneezing attacks 
 ________ Excessive mucus formation Total ________ 
 
MOUTH/THROAT ________ Chronic coughing 
 ________ Gagging, frequent need to clear throat 
 ________ Sore throat, hoarseness, loss of voice 
 ________ Swollen or discolored tongue, gums, lips 
 ________ Canker sores Total ________ 
 
SKIN ________ Acne  
 ________ Hives, rashes, dry skin 
 ________ Hair loss 
 ________ Flushing, hot flashes 
 ________ Excessive sweating Total ________ 
 
HEART ________ Irregular or skipped heartbeat 
 ________ Rapid or pounding heartbeat 






LUNGS ________ Chest congestion 
 ________ Asthma, bronchitis 
 ________ Shortness of breath 
 ________ Difficulty breathing Total ________ 
 
DIGESTIVE TRACT ________ Nausea, vomiting 
 ________ Diarrhea 
 ________ Constipation 
 ________ Bloated feeling 
 ________ Belching, passing gas 
 ________ Heartburn 
 ________ Intestinal/stomach pain Total ________ 
 
JOINTS/MUSCLE ________ Pain or aches in joints 
 ________ Arthritis 
 ________ Stiffness or limitation of movement 
 ________ Pain or aches in muscles 
 ________ Feeling of weakness or tiredness Total ________ 
 
WEIGHT ________ Binge eating/drinking 
 ________ Craving certain foods 
 ________ Excessive weight 
 ________ Compulsive eating 
 ________ Water retention 
 ________ Underweight Total ________ 
 
ENERGY/ACTIVITY ________ Fatigue, sluggishness 
 ________ Apathy, lethargy 
 ________ Hyperactivity 
 ________ Restlessness Total ________ 
 
MIND ________ Poor memory 
 ________ Confusion, poor comprehension 
 ________ Poor concentration  
 ________ Poor physical coordination 
 ________ Difficulty in making decisions 
 ________ Stuttering or stammering 
 ________ Slurred speech 
 ________ Learning disabilities Total ________ 
 
EMOTIONS ________ Mood swings 
 ________ Anxiety, fear, nervousness 
 ________ Anger, irritability, aggressiveness 
 ________ Depression Total ________ 
 
OTHER ________ Frequent illness 
 ________ Frequent or urgent urination 
 ________ Genital itch or discharge 
   Total ________ 
 



































Please list the medications you are currently taking__________________________________ 
____________________________________________________________________________ 
 
Please list any food allergies you have ________________________________________________ 
 _____________________________________________________________________  
 





_____ American Indian or Alaska Native 
_____ Asian  
_____ Black or African American 
_____ Caucasian 
_____ Hispanic  
_____ Native Hawaiian or Other Pacific Islander 




































For the following sheet, please do the following: 
 Indicate the time of consumption in the left column 
 Indicate the foods consumed along with estimated measurements (cup, ounce, 
tablespoon, etc.) in the right column.  
 Include 2 weekdays and 1 weekend day.  
 Please complete each day on a separate sheet.  
 






1 whole egg with 2 egg equivalents of egg beaters 
2 slices of Brownberry 12-Grain bread 
2 Tbsp Skippy peanut butter 
8 oz 1% milk  























































For the following sheet, please do the following: 
 Indicate the date of exercise in the left column 
 Indicate the exercise(s) completed along with number of sets and repetitions in each set in 
the right column.  
 
Date: Exercise(s) Completed: 
 
August 13, 2013 
 
 
3-mile run at 10:15 pace 
4 sets of abdominal crunches, 8 reps each set 


































































Consent to Participate in the Food Elimination Based on ALCAT Testing and the Effect on 
Overall Body Inflammation Study 
You have been invited to participate in a research project sponsored by manufacturer of the 
ALCAT test and designed to test the effect of food elimination on body inflammation and body 
composition. The ALCAT test is a food sensitivity test, and is not equivalent to medical allergy 
testing.  You should continue to avoid foods that you know you have allergies or intolerances, 
regardless, of the ALCAT test results.  This study is being conducted by Dr. Judith Lukaszuk, an 
Associate Professor in Nutrition and Dietetics at Northern Illinois University and Dawn Herbig, 
a graduate level nutrition student and Dietetic Intern at NIU. 
If you meet the requirements of this study to be determined by completion of disease symptom 
inventory, you will be asked to follow an individualized elimination diet based on ALCAT 
testing for four weeks.  Your four weeks will begin about one week following your initial 
screening for this study.  You will be provided with a list of foods to avoid for four weeks. You 
will be randomly assigned to either a control or intervention group.  The control group will 
receive “false” ALCAT reports on their food sensitivities, whereas, the intervention group will 
receive accurate ALCAT report results.  At the end of the study the control group will be 
provided with accurate ALCAT report results. On day 1 of the study 25 mL (or 5 teaspoons) and 
at the end of the study, 21.5 mL (or a little over 4 teaspoons) of your blood will be taken to 
assess food intolerances and to assess  nine inflammatory markers: C-Reactive Protein (CRP), 
Fibrinogen, Interleukin-1 beta (IL-1 beta), Interleukin-6 ( IL-6), Myeloperoxidase (MPO), 
Receptor Activator of Nuclear Factor Kappa-B Ligand  (RANKL),  Serum Amyloid A (SAA), 
Tumor Necrosis Factor alpha (TNF-alpha), and Zonulin. You will report to the nutrition 
laboratory at NIU and have your height, weight, body fat percentage, lean body mass and 
abdominal waist circumference measured at baseline and at the end of the study. All body 
measurements will be taken with subjects in light weight clothing and bare feet.  Height will be 
measured using a wall-mounted stadiometer. Weight, fat mass, percent fat, and fat free mass will 
be assessed using bioelectrical impedance scale called Biospace.  Abdominal circumference will 
be measured with a cloth tape anteriorly halfway between the lowest lateral portion of the 
ribcage and the iliac crest. You must be willing to complete a Medical Symptoms questionnaire 
at the beginning and end of the study as well as 12 weeks after study completion.  You can fill in 
the form via e-mail and send it back to Dr. Judith Lukaszuk at jmlukaszuk@niu.edu. You will 
also be asked to keep a keep a weekly 3 day food record (2 weekdays and 1 weekend day) and an 
exercise log during the study.  We will also be providing you with a questionnaire which asks 
you your ethnicity, what medications you are taking, and what food allergies or food intolerances 
you may have.  
You understand that participation in this study will involve elimination of specific foods based 
on ALCAT test results for the duration of the four-week study. The elimination diets will be 




blood draw will take approximately 15-20 minutes to complete. The anthropometric 
measurements will take about 20 to 30 minutes to complete.  
You are aware that participation is voluntary and may be withdrawn at any time without penalty 
or prejudice, and that if you have any additional questions concerning this study, you may 
contact Dr. Judith Lukaszuk at (815) 753-6352 or Dawn Herbig (847) 927-7808. You understand 
that if you wish further information regarding my rights as a research subject, you may contact 
the Office of Research Compliance at Northern Illinois University at (815) 753-8588. 
You understand that the intended benefits of this study include information of the effects of food 
elimination on body inflammation and body composition. You understand that participation in 
this study is free and you will not be monetarily compensated although you will receive valuable 
information regarding what foods you are intolerant to and how much inflammation you have in 
your body based on the foods you consume.   
You understand that there is the potential risk of infection at the site of the blood draw.  There is 
also a chance you may feel dizzy or light headed during the blood draw.  Please tell us about 
these symptoms.  We will require you to sit in the chair until your symptoms go away.  If your 
symptoms do not go away in 5 minutes you will be provided with fruit juice to drink.  You also 
may ask to stop the blood draw at any time if you feel uncomfortable with the blood draw 
procedure.  Northern Illinois University policy does not provide for compensation for, nor does 
the University carry insurance to cover injury or illness incurred as a result of participation in 
University sponsored research projects. Upon suffering a minor injury, subjects will be referred 
to their PCP or nearest hospital and in the event of serious injury emergency medical services 
will be notified immediately.  
You understand that all information gathered during this study will be kept confidential by 
giving all participants a number that is representative of them, and storing the information in a 
confidential file cabinet, which is locked when not in use. The four-week elimination program 
results information will only be accessible by the researcher and the advisor.  
I understand that my signature below is consent to participate in the Food Elimination Based 
on ALCAT Testing and the Effects on Body Inflammation and Body Composition Study. I 
understand that my consent to participate does not constitute a waiver of any legal rights or 
redress I might have as a result of my participation, and I acknowledge that I have received a 
copy of this form.  
Printed name: _________________________________________________________________ 




















































































































FOOD ELIMINATION BASED ON ALCAT TESTING AND THE EFFECT ON 
OVERALL BODY INFLAMMATION  
 
Debriefing Letter for Control Group Participants 
You were randomly assigned to the control group and as such were provided “false” ALCAT 
report results at the beginning of the study.  Attached are your accurate ALCAT report results.  
Foods included in the red column (indicates a severe intolerance and should be avoided for 6 
months), orange column (indicates a moderate intolerance should be avoided for 3-6 months) and 
yellow column (indicates a mild intolerance should be avoided if possible) should be avoided 
and foods in the green column indicates acceptable foods so you can eat these foods as long as 
you are not allergic to them or have from previous experience with these food reacted with a 
food intolerance.  The ALCAT Company will send out a test results guide booklet, a wallet size 
results card and a meal plan for you to follow based on your ALCAT test results.   However, you 
should consult with your physician before eliminating any foods long term.     
Acknowledgement: 
I, ________________________________, have received my accurate personalized ALCAT test 
results and understand the foods I need to avoid to potentially reduce inflammation in my body.  
 
 






FOOD ELIMINATION BASED ON ALCAT TESTING AND THE EFFECT ON 
OVERALL BODY INFLAMMATION  
 
Debriefing Letter for Intervention Group Participants 
You were randomly assigned to the intervention group and as such was provided “accurate” 
ALCAT report results at the beginning of the study.   Foods included in the red column 
(indicates a severe intolerance and should be avoided for 6 months), orange column (indicates a 
moderate intolerance should be avoided for 3-6 months) and yellow column (indicates a mild 
intolerance should be avoided if possible) should be avoided and foods in the green column 
indicates acceptable foods so you can eat these foods as long as you are not allergic to them or 
have from previous experience with these food reacted with a food intolerance.  The ALCAT 
Company will send out a test results guide booklet, a wallet size results card and a meal plan for 
you to follow based on your ALCAT test results.   However, you should consult with your 
physician before eliminating any foods long term.     
At the conclusion of the study, the participants in the control/placebo group will be un-blinded 
and provided with their ALCAT tests results to determine foods they have sensitivities to and 
therefore need to avoid.  
Acknowledgement: 
I, ________________________________, have received my accurate personalized ALCAT test 
results and understand the foods I need to avoid to potentially reduce inflammation in my body.  
 
 



































Measurement Day One Day 30 
Waist Circumference   





Measurement Day One Day 30 
Body Fat %   
Lean body Mass   
Weight   
 
 
 
